Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tevimbra
Pharma
Takeda, Lilly-Innovent, BIO-China—Fierce Pharma Asia
Takeda launched a restructuring. Innovent notched positive data for a GLP-1R/GCGR agonist. BIO warned of the harm from cutting off Chinese CDMOs.
Angus Liu
May 10, 2024 9:30am
BeiGene finally snags FDA approval for PD-1 drug Tevimbra
Mar 15, 2024 8:39am
BeiGene added 1,400 employees as key cancer drugs expand
Feb 26, 2024 11:03am
Novartis returns PD-1 to BeiGene in another cancer drug divorce
Sep 19, 2023 9:10am
Novartis, BeiGene stage comeback with broader stomach cancer win
Apr 20, 2023 10:55am
BeiGene doubles sales on Brukinsa, tislelizumab strength
Feb 27, 2023 10:56am